JNJ vs NVDA: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and NVIDIA Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-21.
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C
High Quality
VS
NVIDIA Corporation · Technology
$219.76
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
NVDA has more upside to fair value
(+45.0%).
JNJ trades at a lower forward P/E
(26.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
NVDA |
| Current Price |
$230.69 |
$219.76 |
| Fair Value Estimate |
$255.61 |
$318.65 |
| Upside to Fair Value |
+10.8%
|
+45.0%
|
| Market Cap |
$555.9B |
$5,322.7B |
| Forward P/E |
26.8x
|
33.4x
|
| EV / EBITDA |
18.5x
|
27.6x
|
| Price / Sales |
5.8x
|
21.0x
|
| Price / FCF |
28.2x
|
44.7x
|
| Revenue Growth YoY |
+9.9%
|
+85.2%
|
| Gross Margin |
69.1%
|
74.1%
|
| Operating Margin |
26.9%
|
64.0%
|
| Return on Equity |
26.5%
|
111.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.54%
|
2.24%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
NVIDIA Corporation is a leading technology company specializing in semiconductors, primarily known for its GPUs and AI accelerators that power gaming, data center, and professional visualization markets. The company benefits from a durable competitive moat driven by its founder-led management, strong insider alignment, and dominant market share in AI data center chips. NVIDIA's business quality i…
Accumulation Zones
| Metric |
JNJ |
NVDA |
| Zone Low |
$191.71 |
$238.99 |
| Zone High |
$217.27 |
$270.85 |
| In Buy Zone? |
No
|
Yes
|